Evidence map›Paper›PMID 25186177›Full record

ArticleScience translational medicine2014

Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.

Xinhai Wan, Paul G Corn, Jun Yang, Nallasivam Palanisamy, Michael W Starbuck, Eleni Efstathiou, Elsa M Li Ning Tapia, Elsa M Li-Ning Tapia, Amado J Zurita, Ana Aparicio and 13 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 97 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  6. Article
  7. Review
  8. Article
  9. A novel intronic circular RNA circFGFR1Journal of translational medicine · 2023
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 1 country.

Xinhai WanDepartment of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Paul G CornDepartment of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jun YangDepartment of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Nallasivam PalanisamyMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Michael W StarbuckDepartment of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. The Rolanette and Berdon Lawrence Bone Disease Program of Texas, Houston, TX 77030, USA.
Eleni EfstathiouDepartment of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. University of Athens Greece School of Medicine, Athens 11528, Greece.
Elsa M Li Ning Tapia
Elsa M Li-Ning TapiaDepartment of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Amado J ZuritaDepartment of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ana AparicioDepartment of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Murali K RavooriDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Elba S VazquezDepartment of Biological Chemistry, University of Buenos Aires-National Research Council of Argentina (CONICET-IQUIBICEN), Ciudad Autonoma de Buenos Aires C1428EGA, Argentina.
Dan R RobinsonMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Yi-Mi WuMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Xuhong CaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Matthew K IyerMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Wallace McKeehanCenter for Cancer and Stem Cell Biology, IBT-Texas A&M Health Science Center, Houston, TX 77030, USA.
Vikas KundraDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Fen WangCenter for Cancer and Stem Cell Biology, IBT-Texas A&M Health Science Center, Houston, TX 77030, USA.
Patricia TroncosoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Christopher J LogothetisDepartment of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Nora M NavoneDepartment of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. nnavone@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USUniversity of Michigan–Ann Arbor · USMichigan Center for Translational Pathology · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
MICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3M
Targeting Tumor Microenvironment-Induced Therapy Resistance in Prostate Cancer Bone MetastasisP50CA140388 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOGOTHETIS, CHRISTOPHER J., THOMPSON, TIMOTHY CHARLES · 2009 to 2022
$23.4M
Receptor-specific signaling of FGFR in the prostateR01CA096824 · NCI · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI WANG, FEN · 2003 to 2013
$2.5M
FRS2-mediated Signals in Prostatic Tumorigenesis and DevelopmentR56CA096824 · NCI · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI WANG, FEN · 2008 to 2008
$302k
NCI NIH HHS 5P50 CA140388NCI NIH HHS CA96824NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA140388NCI NIH HHS R01 CA096824NCI NIH HHS R56 CA096824NIGMS NIH HHS T32 GM007863PHS HHS RP110555
6 · The paper itself

Abstract

Bone is the most common site of prostate cancer (PCa) progression to a therapy-resistant, lethal phenotype. We found that blockade of fibroblast growth factor receptors (FGFRs) with the receptor tyrosine kinase inhibitor dovitinib has clinical activity in a subset of men with castration-resistant PCa and bone metastases. Our integrated analyses suggest that FGF signaling mediates a positive feedback loop between PCa cells and bone cells and that blockade of FGFR1 in osteoblasts partially mediates the antitumor activity of dovitinib by improving bone quality and by blocking PCa cell-bone cell interaction. These findings account for clinical observations such as reductions in lesion size and intensity on bone scans, lymph node size, and tumor-specific symptoms without proportional declines in serum prostate-specific antigen concentration. Our findings suggest that targeting FGFR has therapeutic activity in advanced PCa and provide direction for the development of therapies with FGFR inhibitors.

Indexed as

AnimalsAntineoplastic AgentsApoptosisBenzimidazolesBone and BonesBone NeoplasmsCell Line, TumorDisease Models, AnimalFibroblast Growth Factor 2Gene Expression Regulation, NeoplasticHumansMaleMiceNeovascularization, PathologicOsteoblastsProstatic Neoplasms4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-oneAntineoplastic AgentsBenzimidazolesFibroblast Growth Factor 2QuinolonesReceptor, Fibroblast Growth Factor, Type 1

Identifiers

PMID25186177
PMCPMC4407499
OpenAlexW2149792874

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.